Low impact
BioNTech Q2 2026 revenue EUR 105.6M missed estimate of EUR 153.9M; adjusted loss per share EUR 2.22 vs EUR 1.45 year-over-year; FY2026 revenue guidance lowered to EUR 1.60B–EUR 1.90B from prior EUR 2.00B–EUR 2.30B.
FirstSquawk08/04, 06:04 PM
Related assets
Coming up for BNTX
Explore next
Latest BNTX news
Jin1008/19, 08:39 PM
Jin1008/19, 06:06 PM
BioNTech (BNTX) rose 14% and Novavax (NVAX) rose 5.8% in US pre-market trading.
ZeroHedge08/04, 07:06 PM